Paris (75), July 3rd, 2024 – Leader in scientific flow control equipment for microfluidics, Elvesys opens its capital and welcomes Yotta Capital Partners, the first French investment fund entirely dedicated to the development and decarbonization of industrial SMEs, along with Arkéa Capital, a Crédit Mutuel Arkéa Private Equity subsidiary, and Arbevel, through its life sciences based Private Equity fund.
Created in 2011 by three microfluidic researchers and led by Éric Farin since 2019, Elvesys has become a major player in microfluidic equipment for academics and industry professionals. Microfluidics refers to the science of fluid flow at the micrometer scale and all associated technologies. Its applications are numerous, spanning biology, physics, industry, and extending to electronic chips and printers, among others.
Elvesys stands out in the pressure-driven microfluidic flow control market, revolutionizing the sector with its cutting-edge high-precision pressure controllers. Its solutions offer precise liquid injection into (micro)circuits at specific pressures and flow rates. By leveraging pressure flow control, Elvesys provides users with enhanced flow stability and accuracy, as well as significantly improved reproducibility compared to traditional methods like syringe pumps and peristaltic pumps.
Through its range of flow regulators and sensors, distribution or recirculation valves, and valve controllers, Elvesys has established itself as a global leader in its market, serving numerous customers across diverse sectors including medical, chemical, physics, cosmetics, and food processing.
Guilhem Velve Casquillas, co-founder, stated: “For several years now, microfluidic technologies have reached a level of maturity that enables widespread adoption by industries, especially in the medical field. Beyond miniaturization, microfluidic technologies allow for the replication of the human cellular environment with unmatched precision. This paves the way for numerous applications, whether for the development of new drugs or the advent of truly effective and accessible personalized medicines.”
With the arrival of Yotta, Arkéa Capital, and Arbevel as shareholders, the company aims to accelerate its growth both in France and internationally. This will be achieved through forging new partnerships and strengthening Elvesys’ commercial team, particularly in expanding its OEM offerings for industrial clients. Additionally, the company plans to ramp up its R&D efforts to enhance its existing product portfolio and introduce a range of instruments specifically tailored for biologists to the market.
“Microfluidics is a highly promising technology with numerous applications, particularly in medical, biological, and cosmetic fields, and France enjoys a global scientific great reputation. Elvesys contributes to this reputation, and we aim to support them in accelerating their development. We also seek to bring our expertise in addressing environmental challenges to their processes and products”, stated Xavier Herrmann and Tristan Eliard, from Yotta Capital Partners.
“Arkéa Capital is pleased to support Elvesys, which managed through innovation, dedication, and pragmatism of its teams, to offer a comprehensive solution to academic and industrial players in an emerging market. This perfectly aligns with our DNA as a supporter and accelerator of growth”, added Nouria Barnat, Director of Investments at Arkéa Capital.
“We are excited to support Elvesys, an innovative company with numerous applications in healthcare and strong potential. Their expertise in microfluidics opens exciting prospects for biomedical research, both through academics and industrials. Alongside the management team, we are eager to leverage our experience to contribute to their development”, added Louis Geslin, Managing Partner at Arbevel.
Éric Farin, CEO of Elvesys, stated: “Since its inception, Elvesys’ mission has been to accelerate our clients and partners projects in the fields of research and innovative industries by providing them with the most advanced solutions, technologies, instruments, systems, and services possible. We were looking for investors to support the investments we plan to make in the next 5 years and genuine partners capable of supporting us in this journey of excellence and growth. Our choice naturally fell on Yotta, Arbevel, and Arkéa Capital due to their sensitivity to social and environmental issues, their entrepreneurial philosophy, and their track record. The Elvesys team and I are particularly excited to embark on this new chapter in the company’s life, which will see the development of new product and service ranges with our partners.”
Finally, the company’s growth plan may be supplemented by targeted external growth operations to expand its product range or acquire additional technological features.
About Elvesys
Elvesys Group is a leading French SME among microfluidics stakeholders. The group develops an advanced range of microfluidic instruments for various applications. Their microfluidic systems find utility across diverse fields including biology, chemistry, drug delivery, as well as cosmetics and food industries.
More information on: www.elveflow.com
Contact: 01 84 16 38 07 – contact@elveflow.com
About Yotta Capital Partners
Yotta Capital Partners is a Private Equity and buyout fund dedicated to the Industry of the Future. With 25 years of experience, its hybrid team is made up of Private Equity and industrial professionals. Committed to the environment, Yotta Capital Partners invests in French small and medium-sized industrial companies through two funds: Yotta Smart Industry, dedicated to industrial SMEs, and Yotta Growth Industry, which supports industrial scale-ups. The Yotta platform provides them with strong support in modernization, growth, and decarbonization challenges, helping them navigate through the fourth industrial revolution. Yotta Capital is a member of the IC 20 and has been awarded the French “Label Relance” and Tibi 2.
More information on: www.yottacapital.fr
Contact: 01 81 70 88 50 – ycp@yottacapital.fr
About Arkéa Capital
Arkéa Capital, as a minority shareholder, supports companies ranging from startups to mid-sized companies at every stage of their development while maintaining the independence of decision-making centers. As a Crédit Mutuel Arkéa Private Equity subsidiary, Arkéa Capital has been active for over 40 years across all sectors throughout France, thanks to an experts team and seven regional offices (Brest, Nantes, Paris, Rennes, Bordeaux, Strasbourg, and Lyon. It provides long-term support to businesses and their leaders through eight complementary investment vehicles: Arkéa Capital Investissement, Arkéa Capital Partenaire, Arkéa Capital 2, Breizh Ma Bro, Breizh Armor Capital, Arkéa Cap’Atlantique, We Positive Invest, and We Positive Invest 2. With a presence in over a hundred companies, Arkéa Capital manages over €1.3 billion in assets under management.
More information on: www.arkea-capital.com / Linkedin: Follow our news
Press contact: Kablé Communication – Lucie Lelong : 06 45 69 81 57 – lucie.lelong@kable-communication.com
About Arbevel
Founded in 1997 and acquired by its current managers in 2009, Arbevel is an entrepreneurial asset management firm originally specialized in managing listed equity and bond funds. Arbevel has progressively diversified to become a multi-specialist in asset management, relying on three pillars: (i) fund management, overseeing €1 billion in assets under management across well-defined strategies (equities, bonds, and diversified funds), (ii) discretionary portfolio management, and (iii) Private Asset management, encompassing two generations of Private Equity and Private Debt funds.
With its diverse offerings, the group addresses various customer portfolio including institutional investors, family groups, wealth management specialists, and private customers.
More information on: https://arbevel.com
Contact: 01 56 59 11 33 – flhenoret@arbevel.com
List of contributors
Investors: Yotta Capital Partners, Xavier Herrmann, Tristan Eliard, Grégoire Musy ; Arkéa Capital, Cyril Miller, Nouria Barnat, Charlène Grept ; Arbevel, Louis Geslin, Astré Bouchier, Rodolphe Besserve ; Founders, Guilhem Velve Casquillas, Mathieu Velve Casquillas, Adrien Plecis, Mael Le Berre, Christophe Pannetier ; Managers, Éric Farin, Maude Maréjus, David Bretaud, Sébastien Cargou.
Sellers: Founders, Guilhem Velve Casquillas, Mathieu Velve Casquillas, Adrien Plecis, Mael Le Berre, Christophe Pannetier.
M&A advisors – Sell-side: Edmond de Rothschild, Jules Bouvet, Guillaume Lallouet, Augustin Peyronne.
Legal advisors – Sell-side: Alternative Avocats, Olivier Savelli, Inaya Abdellatif.
Legal advisors for Investors – Corporate: Lamartine Conseil, Gary Lévy, Solange Ducos, Raphaël Saulneron et Juliette Guislain.
Legal advisors for Investors – Fiscal: Lamartine Conseil, Bertrand Hermant et Maxence Colcombet.
Legal advisors for Investors – Social: Lamartine Conseil, Charlotte Moreau, Patricia Volpe et Manon Mestres.
Legal advisors for Investors – IP: Lamartine Conseil, Benoit Philippe et Audrey Freeman.
Legal advisors for Investors – Senior debt: Lamartine Conseil, Maryline Pic-Dehongher.
Financial Vendor Due Diligence: Eight Advisory, Sandrine Vouillon, Guillaume Roque, Paul Ferrage.
Financial Due diligence – Investors: Alvarez & Marsal, Benoit Bestion, Thibault de la Taille, Jean-Baptiste Dujardin, Tanguy Voisin.
ESG/Carbone Due Diligence: Carbone 4, Lucile Brand ; Ethifinance, Salomé Martin.
Senior debt: BNP Paribas, Daniel Ardeljan,
